In recent years, the field of hematologic malignancies has witnessed numerous groundbreaking advancements, with Chinese researchers making increasingly significant contributions, particularly in the area of cellular therapy. Their work has greatly accelerated both academic development and clinical practice in this domain. As we step into the new year, Hematology Frontier has invited Dr. Wenbin Qian from The Second Affiliated Hospital of Zhejiang University School of Medicine to provide an in-depth review of CAR-T cell therapy for B-cell lymphoma, summarizing approved CAR-T products, clinical trial data, real-world outcomes, and ongoing challenges. Additionally, this discussion explores strategies for enhancing CAR-T therapy, including novel targets, dual-target CAR-T designs, and gene-editing improvements, aiming to offer valuable insights for clinical practice and future research directions.
